Intravenous ibuprofen offers advantages over oral ibuprofen such as higher bioavailability and immediate relief in acute pain conditions. It helps reduce opioid consumption for pain relief and facilitates faster recovery. The need for alternative pain management therapies has fueled adoption of IV ibuprofen formulations in hospitals and ambulatory care settings.

The global intravenous (IV) ibuprofen market is estimated to be valued at US$ 11.13 billion in 2024 and is expected to exhibit a CAGR of 7.1% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the intravenous (IV) ibuprofen market are Cumberland Pharmaceuticals Inc., Hyloris Pharmaceuticals SA, Grifols, S.A., Recordati Rare Diseases Inc., XGEN PHARMACEUTICALS DJB, Inc., AFT Pharmaceuticals, Laboratorios Valmorca, SGPharma Pvt. Ltd., Wellona Pharma, Delex Pharma, and Hikma Pharmaceuticals PLC. Cumberland Pharmaceuticals holds a majority market share with its brand Iveegel approved for treatment of acute pain in children and adults. The market sees opportunities in expanding IV ibuprofen indications for post-operative pain management and fever reduction. Major players are investing in clinical trials for new formulations and line extensions. Globally, the market is witnessing rapid growth in Asian countries led by China and India due to rising medical infrastructure and demand for improved pain therapies.

Market Drivers

Reduction in opioid consumption: Intravenous (IV) Ibuprofen Market Size provides effective pain relief and reduces reliance on opioids that have abuse and addiction potential. This majorly drives its adoption across healthcare settings.

Emergence of multi-dose vials: availability of multi-dose vials of IV ibuprofen allows for treatment of multiple patients with a single vial, improving affordability and cost-effectiveness. This boosts the market growth.

Market Restraints

Stringent regulatory approval process: The regulatory standards for approval of intravenous pharmaceuticals are very high. This increases clinical trial timelines and costs, limiting new market entrants.

Availability of alternatives: The presence of several affordable generics and alternatives for pain management such as paracetamol acts as a restraint for the intravenous ibuprofen market.

Segment Analysis
The global intravenous (IV) Ibuprofen market is segmented based on application, end-user and region. The application segments include pain and fever. Among these, the pain segment accounted for the highest market share in 2024. This is because IV Ibuprofen is highly effective in treating mild to moderate pain associated with surgical procedures and medical conditions.

Get more insights on This Topic- Intravenous (IV) Ibuprofen Market